Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

800 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M. Hamann A, et al. Among authors: donaldson j. Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. doi: 10.1055/s-2007-984441. Epub 2007 Dec 20. Exp Clin Endocrinol Diabetes. 2008. PMID: 18095238 Clinical Trial.
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.
López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. López A, et al. Among authors: donaldson j. Crit Care Med. 2004 Jan;32(1):21-30. doi: 10.1097/01.CCM.0000105581.01815.C6. Crit Care Med. 2004. PMID: 14707556 Clinical Trial.
Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, Guntupalli K, Grossman S, Donaldson J, Le Gall JR; Glaxo Wellcome International Septic Shock Study Group. Watson D, et al. Among authors: donaldson j. Crit Care Med. 2004 Jan;32(1):13-20. doi: 10.1097/01.CCM.0000104209.07273.FC. Crit Care Med. 2004. PMID: 14707555 Clinical Trial.
Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J; Glaxo Wellcome International Septic Shock Study Group. Bakker J, et al. Among authors: donaldson j. Crit Care Med. 2004 Jan;32(1):1-12. doi: 10.1097/01.CCM.0000105118.66983.19. Crit Care Med. 2004. PMID: 14707554 Clinical Trial.
800 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page